GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 ...

GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...

In addition, due to increased demand, many GLP-1 agonists are listed on the FDA’s Drug Shortages list. People also must consider their comfort level regarding injections, which is the form of ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but in how she thought about food. Where the smell of hot chips in the deep ...

GLP-1 and the risk of suicidality The GLP-1 receptor agonist drug class is widely prescribed to manage T2D. These medications are highly effective in achieving glycemic control while also ...

There had also been concern that GLP-1 agonists might increase the risk for a rare form of thyroid cancer in patients already taking immune-suppressing drugs to prevent transplant rejection ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor ... psychiatric safety of these drugs,” the authors write.